Effects of Tranexamic Acid on Hemoptysis: A Systematic Review and Meta-analysis

doi:10.21203/rs.3.rs-65330/v1

Download PDF

Research

Effects of Tranexamic Acid on Hemoptysis: A Systematic Review and Meta-analysis

https://doi.org/10.21203/rs.3.rs-65330/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background:

Although tranexamic acid (TXA), a readily accessible antifibrinolytic agent, is widely adopted in hemorrhage scenarios, its role in patients with hemoptysis remains uncertain. New evidence is yet to be generated to evaluate the efficacy and safety of TXA in patients with hemoptysis.

Methods:

PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus databases were searched from inception to May 2020. Randomized controlled trials and observational studies that evaluated the effect of TXA on patients with hemoptysis were included. Data were independently extracted by two reviewers and synthesized using a random-effects model.

Result:

Five studies with a total of 20,047 patients were analyzed. When compared with the control, administration of TXA was associated with a reduction in short-term mortality (risk ratio [RR] = 0.78, 95% confidence interval [CI] 0.72 to 0.85; I²= 0), shorter bleeding time (mean difference [MD] = −24.61 hours, 95% CI −35.96 to −13.26, I² = 0), shorter length of hospital stay (MD = −1.94 days, 95% CI −2.48 to −1.40, I² = 0), and lower need for intervention (RR = 0.38, 95% CI 0.16 to 0.87, I² = 0) in patients with hemoptysis. Compared with control, administration of TXA did not cause increased major or minor adverse effects.

Conclusion:

TXA provided benefits in terms of a lower short-term mortality rate, less bleeding time, shorter length of hospital stays, and less need for intervention in patients with hemoptysis. Use of TXA was not associated with increased adverse effects.

Trial registration:

PROSPERO; No.: CRD42020185062; URL: https://www.crd.york.ac.uk/prospero/.

Critical Care & Emergency Medicine

Tranexamic acid

hemoptysis

mortality

Hemoptysis, which can result from various etiologies, with malignancy, pulmonary infection, and bronchiectasis listed as the three leading causes, remains a challenging condition for physicians.(1) The clinical manifestations range from a nonalarming bloody expectoration to a life-threatening bleeding condition. Approximately 5–14% of patients presenting with hemoptysis will have life-threatening hemoptysis(2), with a reported mortality rate between 9% and 38%.(3) The amount of blood expectorated may be associated with in-hospital mortality.(4) Additionally, a recent French nationwide study indicated that 9.0% of patients who were hospitalized for hemoptysis required admission to the intensive care unit.(5) The reported average length of hospital stay among these patients is approximately 8 days.(5) Furthermore, Petersen et al. reported a recurrence rate of 8.7% within 5 years of follow-up in patients with hemoptysis.(6)

A guideline recommends that prompt intervention, including bronchial artery embolization, bronchoscopy, and surgical lung resection, is imperative in patients with massive hemoptysis.(7) Meanwhile, in patients with mild hemoptysis, the course is mostly self-limited under adequate infection control.(7) However, evidence regarding conservative and medical treatment in patients with sub-massive hemoptysis is lacking.

Tranexamic acid (TXA), a synthetic lysine analog, is a commonly used antifibrinolytic agent that controls bleeding by inhibiting the conversion of plasminogen to plasmin. TXA has been widely used in the last two decades to reduce bleeding. Previous studies have indicated that TXA reduces mortality in patients with postpartum hemorrhage(8) or major trauma.(9) In addition, the administration of TXA shortened the duration of epistaxis in patients with hereditary hemorrhagic telangiectasia.(10) However, the role of TXA in patients with hemoptysis is uncertain. A Cochrane review in 2013 and another meta-analysis in 2016 have found that systemic TXA is efficient in shortening the bleeding period.(11, 12) However, the effect of TXA on mortality, need for intervention, and length of hospital stay in patients with hemoptysis is still unclear, and additional studies in this regard are warranted. Three studies have since investigated the efficacy of TXA in hemoptysis.(13–15) Through this study, we aimed to update and synthesize the evidence on the efficacy and safety of TXA in patients with hemoptysis.

Our meta-analysis followed the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.(16) The analysis was registered at PROSPERO (PROSPERO ID: CRD42020185062).

Search strategy

To identify relevant evidence, two authors (LFC and YPH) independently searched PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus from their first record to May 2020. The key search text words and MeSH terms were as follows: tranexamic acid, antifibrinolytic agents, and hemoptysis. The details of the search are provided in Additional file 1. No language restrictions were imposed. The reference sections of the identified studies and previous systematic reviews were manually examined for additional potential studies. The ClinicalTrials.gov registry (http://clinicaltrials.gov/) was also searched for unpublished studies.

Inclusion and exclusion criteria

All published human randomized controlled trials (RCTs) or observational studies with an adequate control group were included. The participants were either adult or pediatric patients presenting with hemoptysis of any etiology and severity. The intervention was administration of TXA via any route and any regimen. Patients in the control group were treated with a placebo or were provided no treatment. Case reports, case series, abstracts, and animal studies were excluded. Our primary outcome of interest was the mortality rate. The secondary outcomes were cessation of the bleeding rate, duration of bleeding, amount of blood loss, need for intervention, length of hospital stay, and recurrence rate. Safety outcomes were major adverse events, such as venous thromboembolism, coronary artery occlusion, and stroke, which were attributable to the mechanism of action of TXA, and minor adverse events, such as nausea, dizziness, vomiting, abdominal pain, and diarrhea.

Data extraction and management

Two reviewers (LFC and CHY) independently extracted the data. The following information was extracted: first author, publication year, country, study design, sample sizes, inclusion and exclusion criteria, baseline characteristic, regimens of each intervention, and data of the outcome interest. Any controversies regarding recorded data were resolved through discussion between the authors or by consulting a third reviewer (YPH).

Assessment of risk of bias

Two investigators (TYL and PJP) independently assessed the methodological qualities of the included studies. The Cochrane risk of bias tool 2.0 for RCTs was used.(17) This tool includes six domains: selection bias due to the inadequate generation of a randomized sequence or concealment of allocation before the assignment, performance bias due to the knowledge of allocated interventions by participants and personnel, detection bias due to the knowledge of allocated interventions by outcome assessors, reporting bias due to selective outcome reporting, and other biases. The Newcastle–Ottawa scale tool was applied to assess the quality of observational studies.(18) Studies were evaluated by selection with a maximum of four stars, comparability with a maximum of two stars, and outcome with a maximum of three stars. Studies with cumulative stars ≥ 7 were considered to be of high quality. If no agreement could be reached, a third investigator (YPH) determined the rating.

Statistical analysis

Data were analyzed using Review Manager (version 5.3, Copenhagen, Denmark). Meta-analyses were performed using a random-effects model. For binary outcomes, the risk ratio (RR) was estimated with the 95% confidence interval (CI). The MD and 95%CI were used to estimate continuous outcomes. Significant differences between the groups were set at two-sided P values smaller than 0.05. Heterogeneities among the studies were estimated using the I² statistic. The statistical heterogeneity was categorized into low (25–50%), moderate (50–75%), or high (> 75%) according to the I² values.(19) In case of substantial heterogeneity, factors that could potentially affect the magnitude of the treatment response were explored using prespecified subgroup analysis (route of administration). If at least 10 studies were included, publication bias was assessed by detecting the asymmetry in funnel plots and using the Egger’s test.(20)

Study characteristics

The flow diagram of literature search is displayed in Fig. 1. In total, 1871 studies were retrieved from different sources, including PubMed, EMBASE, Scopus, the Cochrane Library, Web of Science, clinicaltrials.gov, and manual search. Subsequently, 630 duplicated records were removed and 1190 articles were excluded after screening titles and abstracts. The full text was then extracted to assess the eligibility. Eventually, six and five studies were included for qualitative and quantitative analysis, respectively, because Alberto-Pasco et al. reported the outcome of interest as a composite of mortality and requirement for blood transfusion.(13–15, 21–23)

The characteristics of the included studies are summarized in Table 1. These studies were conducted in Peru, Thailand, Israel, India, and Japan. Four studies were RCTs, one was a retrospective cohort study, and one was a case control study. Five studies enrolled inpatients and one study included both inpatients and outpatients. Three studies excluded patients with massive hemoptysis, and the threshold for massive hemoptysis varied among studies. Additionally, two RCTs excluded patients with renal failure. Five studies comprised patients with hemoptysis due to all etiologies, and one study comprised patients with hemoptysis due to only tuberculosis. Sample sizes ranged from 24 to 19866 patients, with mean patient ages ranging from 40.1 to 72 years. TXA was administered through inhalation in one study, oral route in one study, and intravenous (IV) route in three studies; one study did not provide information regarding the route of administration. The dosage of TXA varied among studies.

Table 1

Characteristics of included studies
Author, publication year	Country	Study design/ setting	Inclusion criteria	Cause of hemoptysis	Sample size, N	Age, mean (SD)	Intervention	Control
			Exclusion criteria
Ruiz, 1994²¹	Peru	RCT/In-patient	N/A	Tuberculosis	TXA: 13	TXA: N/A	TXA IV 1000 mg TID	Placebo
			N/A		Control: 11	Control: N/A
Tscheikuna et al., 2002²²	Thailand	RCT/In-patient and out-patient	Patient with hemoptysis	Any cause	TXA: 21	TXA: 45.38 (15.43)	TXA PO 500 mg TID/	Placebo
			Bleeding ≥ 500 mL/day		Control: 25	Control: 40.46 (13.67)
Bellam et al., 2016¹⁴	India	RCT/In-patient	Patient with acute-onset, ongoing hemoptysis	Any cause	TXA: 43	TXA: 42.63 (16.6)	TXA IV 1000 mg STAT + 1000 mg Q8H/	Placebo
			Bleeding ≥ 600 mL/day Renal failure		Control: 21	Control: 40.1 (13.6)
Wand et al., 2018¹³	Israel	RCT/In-patient	Patient with hemoptysis in past 24 hours	Any causes	TXA: 25	TXA: 68 (N/A)	TXA Nebulized 500 mg TID	Nebulized NS
			Bleeding ≥ 200 mL/day Respiratory and hemodynamic instability Renal failure Coagulopathy		Control: 22	Control: 69 (N/A)
Kinoshita et al. 2019¹⁵	Japan	OS/In-patient	Patient admitted owing to hemoptysis	Any causes	TXA: 9933	TXA: 72 (14)	TXA IV of uncertain dose and frequency	No TXA
			Hemoptysis after admission		Control: 9933	Control:72 (13)
Alberto-Pasco, 2013²³	Peru	CC/In-patient	Patient admitted owing to hemoptysis	Any causes	TXA: 45	Median = 35	TXA of uncertain route, dose and frequency	No TXA
			N/A		Control: 35
C: control group; CC: case–control study; IV: intravenous; N/A: not applicable; NS: normal saline; OS: observational study; PO: per Os; RCT: randomized controlled trial; TXA: tranexamic acid

Risk of bias assessment

The assessment of risk of bias is shown in Additional file 2. Among RCTs, the study by Tscheikuna et al. had an unclear selection bias, because the randomization protocol was not mentioned. Ruiz et al. found a high risk of attrition bias because they did not perform the intention-to-treat analysis; the reporting bias was evaluated as unclear owing to the lack of protocol disclosed. The remaining two RCTs were rated as low-risk bias. For observational studies, one study was rated as a high-quality study (scored 8 stars); the study by Alberto-Pasco et al. was rated as a low-quality study because of limited information regarding population selection, comparability, and exposure details.

Primary outcome: overall mortality

Three studies (n = 19,937) reported the comparison between the mortality rate when TXA and control were used for the treatment of hemoptysis. TXA was administered through the IV or inhalation route. One study investigated the effect of TXA on in-hospital mortality, one on short-term mortality, and one on 30-day mortality rate. We regarded these reported outcomes as sharing a similar property of short-term mortality rate. The pooled result indicated that using TXA was associated with reduction in the short-term mortality rate (RR = 0.78, 95%CI 0.72 to 0.85; Fig. 2). There was no significant heterogeneity between the groups (I² = 0%). A subgroup analysis for patients receiving IV TXA (n = 19890) also indicated a reduction in short-term mortality (RR = 0.78, 95%CI 0.72 to 0.85; Fig. 4a). Wand et al. reported the effect of TXA on long-term mortality. The result showed that using nebulized TXA significantly reduced the 1-year mortality rate compared with the control (n = 47, 16% vs. 18%, P < 0.01).

Secondary outcome

Cessation of bleeding

Two studies (n = 93) reported on the cessation of bleeding rate following TXA administration compared with the control. One study evaluated the bleeding status 7 days after oral TXA treatment, and another study evaluated the rate of bleeding resolution 5 days after TXA treatment through nebulization. A total of 41 of 46 (89.1%) patients who received TXA achieved cessation of bleeding, compared with 29 of 47 (61.7%) patients who received the control (RR = 1.44, Fig. 3a). However, the pooled results were not statistically different.

Time required to stop bleeding

Two studies (n = 70) investigated the time in which bleeding stopped after the treatment. In both the studies, TXA was administered systemically; one intravenously and one orally. Forest plots indicated that compared with patients treated with the control, those treated with TXA had a significantly shorter bleeding time (MD = − 24.61 hours, 95% CI − 35.96 to − 13.26, I² = 0; Fig. 3b).

Bleeding volume

In three studies, the bleeding volume after treatment was measured between the groups. The method and time point of measurement varied among studies. Therefore, we did not pool the results. Ruiz et al. did not provide information regarding measurement of the bleeding volume and the variance of the effect sizes. They reported a significant reduction of bleeding volume after treatment with IV TXA. In the study by Bellam et al., the bleeding volume was measured on Day 1 and Day 2. They found that compared with the control, treatment with IV TXA reduced the bleeding volume on Day 1 (84.3 mL vs. 145 mL) and Day 2 (34.19 mL/day vs. 90.4 mL). In the study by Wand et al., the bleeding volume was measured as milliliters per 24 hours. The daily bleeding volume significantly reduced since Day 2 when patients were treated with TXA through nebulization compared with the placebo.

Length of stay

Three studies (n = 19977) provided information on the hospital length of stay. Two studies used intravenous TXA and one study used nebulized TXA. The result showed that the length of stay was significantly shorter in the TXA group than in the control group (MD = − 1.94 days, 95% CI − 2.48 to − 1.40, I² = 0; Fig. 3c). A subgroup analysis was performed on two studies (n = 19930) using IV TXA. The result indicated that patients receiving IV TXA had a significantly shorter length of stay compared with those receiving the control (MD = − 1.93 days, 95% CI − 2.49 to − 1.37 days, I² = 0; Fig. 4b).

Need for intervention

Two studies (n = 111) investigated whether patients with hemoptysis still required the intervention for hemostasis after medication. The procedure included surgery, bronchoscopy, or bronchial artery embolization. The pooled result revealed that TXA administration significantly reduced the need for intervention, compared with the controls (RR = 0.38, 95% CI 0.16 to 0.87, I² = 0; Fig. 3d).

Recurrence

The recurrence of hemoptysis was assessed in three studies (n = 135). In two of these studies, TXA was administered through the IV route, and in one study, it was administered through nebulization. Hemoptysis recurring within 1 month or during the hospitalization was termed as short-term hemoptysis recurrence. A total of 5 out of 81 (6.2%) patients who received TXA had short-term recurrent hemoptysis compared with 8 out of 55 (14.5%) patients who received the control (RR = 0.40, Fig. 3e). However, the pooled results were not statistically different. Wand et al. reported that patients administered TXA through nebulization had a significantly lower recurrence rate within 1 year compared with those administered the control (n = 47, 4% vs. 22.7%, P < 0.01).

Safety

No major complications, such as thromboembolic events, were observed in any of the clinical trials. In the large retrospective study, no significant difference was recorded in terms of thromboembolism (TXA 2.3% vs. control 2.1%, P = 0.34) and seizure (TXA, 5 in 9933 cases vs. control, 9 in 9933 cases). All clinical trials (n = 191) documented minor adverse effects associated with TXA, including nausea, dizziness, and gastrointestinal upset. The pooled result showed no significant difference between TXA and control groups with regard to minor adverse effects (Additional file 3).

The principal finding of our study is that administration of TXA was associated with a reduction of the short-term mortality rate. IV administration of TXA also reduced short-term mortality in that subset of patients. TXA use led to a shorter bleeding time, lower bleeding volume, shorter length of hospital stay, and less requirements for intervention compared with the control. Administration of TXA was not associated with the recurrence of hemoptysis or increase in major or minor adverse effects.

Expectoration of large amounts of blood is associated with high morbidity and mortality. Advances in medical imaging, fiberscope technology, and interventional radiology have led to improved outcomes, with the reporting mortality rates ranging from 7–30% since 2000.(24–26) However, a strong recommendation regarding pharmacological treatment, such as antifibrinolytic agents for hemoptysis, does not exist.(27–29) TXA is an antifibrinolytic agent that is commonly used to control bleeding, and it has recently been proven a promising strategy to reduce mortality from hemoptysis.(13) Our study provided a comprehensive search from five databases and involved manual checking of the relative reviews and references to identify eligible studies. In total, 19943 patients were included, a number that was significantly larger than that of patients in the latest systematic review (n = 322).(28) We found that TXA administration consistently led to a 22% reduction in shorter-term morality. Moreover, a consistent reduction in short-term mortality by 22% was observed in a subset of patients receiving IV TXA. Additionally, according to the study by Wand et al., treatment with TXA through inhalation reduced the long-term mortality by 2%. In accordance with our findings, previous large-scale clinical trials have demonstrated that administration of TXA reduced the mortality of patients during uncontrolled post-partum hemorrhage and traumatic bleeding.(8, 9) This updated evidence, with more studies and more precise effect estimates (narrower CIs), reduces the uncertainty around the results.

Mild hemoptysis tends to stop spontaneously in some cases.(22) For hemoptysis greater than or equal to 1 liter per 24 hours, a mortality rate up to 58% was reported.(30) Among cases of fatal hemoptysis, the inciting cause of death is asphyxiation from inability to oxygenate or ventilate because of the hemorrhage flooding the airways.(31) The volume of the conducting airway is approximately 150 mL,(32) and a nonsignificant amount of pulmonary bleeding may hinder oxygenation before hemodynamics becomes unstable.(33) Therefore, it is critical to reduce the bleeding volume and foster bleeding cessation. Our study showed that patients in the TXA group showed earlier bleeding cessation by 24.3 hours compared with those in the control group. In addition, the results from three RCTs indicated that the administration of TXA reduced the bleeding volume. However, we did not observe any benefit of TXA in terms of the hemoptysis cessation rate. This could be attributed to the small number of the included studies with small sample sizes. Additional large clinical trials should be conducted to prove or disapprove our hypothesis.

The length of hospital stay is an important indicator of the patient quality of care and functional evaluation. Decreased length of hospital stay was associated with decreased medical costs in patients with hemoptysis.(15) Our study demonstrated that administration of TXA significantly reduced the length of stay by 1.94 days. In consistency with our observation, TXA administration to patients suffering from truncal and peripheral vascular trauma led to a 4-day shortening of hospital period, compared with placebo.(34) The explanation of this finding was that TXA provided better bleeding control, which may cause less morbidity during a hemoptysis episode, resulting in early discharge.

The requirement of embolization or surgical intervention to treat hemoptysis indicates additional medical efforts, risk of surgery, and anesthesia complications. A recent large RCT showed that TXA administration failed to reduce the requirement of surgical, endoscopic, or radiological intervention in patients with acute gastrointestinal bleeding.(35) In contrast, TXA reduced the requirement for Brace suture and laparotomy surgery in patients with postpartum hemorrhage.(8) There is little evidence about the pharmacological effect of hemoptysis on the need for hemostasis intervention. In our study, we observed that TXA reduced the requirement of further interventions by 62%.

A major concern with the application of TXA was the increase of thromboembolic events. TXA is associated with more than threefold increased odds of venous thromboembolism in patients with trauma.(36) Moreover, some studies showed that TXA administration led to a 6–11% increase in postoperative seizure among patients who underwent cardiac surgery.(37, 38) In addition, a case report had raised the concern that TXA administration led to pulmonary embolism in patients with chronic hemoptysis secondary to bronchiectasis.(39) However, in our study, no increased major adverse events were observed in the included RCTs.(13, 14, 21, 22) Further, TXA administration did not increase the incidence of thromboembolic events and seizure in a large-scale included observational study.(15) Therefore, TXA seemed safe for hemoptysis control.

Although our meta-analysis demonstrated the benefit of TXA for hemoptysis, it has several limitations. First, limited studies were included and the case numbers of the RCTs involved were relatively small. Second, observational studies were also included, which could have introduced a selection bias. Third, the length of treatment, dosage and form of TXA administration, and the definition of severity of hemoptysis varied among the studies, which may introduce clinical heterogeneities. However, significant statistical heterogeneities were observed only at the analysis of the hemoptysis cessation rate. Fourth, some factors, such as smoking, malignancy, pulmonary infection, and anti-coagulant drug use,(40–42) were associated with increased rate of mortality and hemoptysis recurrence. These confounding factors were not fully disclosed in some studies (Additional file 4). Moreover, most of the studies included all etiologies of hemoptysis, except one study that specifically dealt with tuberculosis-related hemoptysis. Therefore, whether the results of our study could be generalized to a specific population warrants further investigation. Finally, a funnel plot for assessing publication bias was not depicted owing to the small number of studies included.

Our meta-analysis indicated that administration of TXA was associated with a reduction of short-term mortality rate, shorter time required to stop bleeding, shorter length of hospital stays, and less requirement of intervention among patients with hemoptysis. TXA is considered a safe medication for hemoptysis.

Confidence interval, IV = intravenous, MD = Mean difference, RR = Risk ratio, RCT = Randomized controlled trial, TXA = Tranexamic acid

Ethical approval and consent to participate

Not obtained as this is a systematic review and meta-analysis of published

studies.

Consent for publication

Not applicable.

Availability of data and material

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

The authors Liang-Fu Chen, Ting-Yi Lin, Po-Jia Pao, Karen Chia-Wen Chu, Chih-Hao Yang, Jer-Hwa Chang, Chin-Wang Hsu, Chyi-Huey Bai, and Yuan-Pin Hsu are grateful for the ﬁnancial support provided by project NO. 109-wf-eva-25 of Wan Fang Hospital, Taipei Medical University, Taiwan.

Author’s contribution

Yuan-Pin Hsu and Liang-Fu Chen had full access to all data in the study and take responsibility for data integrity and accuracy of data analysis.

Concept and design: Liang-Fu Chen and Yuan-Pin Hsu

Acquisition, analysis, or interpretation of data: Liang-Fu Chen, Chih-Hao Yang, Ting-Yi Lin, Po-Jia Pao, Karen Chia-Wen Chu, and Jer-Hwa Chang

Drafting of manuscript: Liang-Fu Chen and Yuan-Pin Hsu

Statistical analysis: Chin-Wang Hsu and Chyi-Huey Bai

Study supervision: Yuan-Pin Hsu

Acknowledgements

This manuscript was edited by Wallace Academic Editing.

Mondoni M, Carlucci P, Job S, Parazzini EM, Cipolla G, Pagani M, et al. Observational, multicentre study on the epidemiology of haemoptysis. The European respiratory journal. 2018;51(1).
Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997;112(2):440–4.
Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respir Int Rev Thorac Dis. 2010;80(1):38–58.
Dweik RA, Stoller JK. ROLE OF BRONCHOSCOPY IN MASSIVE HEMOPTYSIS. Clin Chest Med. 1999;20(1):89–105.
Abdulmalak C, Cottenet J, Beltramo G, Georges M, Camus P, Bonniaud P, et al. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. Eur Respir J. 2015;46(2):503–11.
Petersen CL, Weinreich UM. Five-year follow-up of hemoptysis with no malignancy suspected on chest computed tomography: recurrence, lung cancer and mortality. European Clinical Respiratory Journal. 2019;6(1):1616519.
Earwood JS, Thompson TD. Hemoptysis: evaluation and management. Am Family Phys. 2015;91(4):243–9.
Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, Akintan A, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2017;389(10084):2105–16.
Effects of tranexamic acid on. death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. The Lancet. 2010;376(9734):23–32.
Gaillard S, Dupuis-Girod S, Boutitie F, Rivière S, Morinière S, Hatron PY, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494–502.
Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database of Systematic Reviews. 2012(4).
Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database of Systematic Reviews. 2016(11).
Wand O, Guber E, Guber A, Epstein Shochet G, Israeli-Shani L, Shitrit D. Inhaled Tranexamic Acid for Hemoptysis Treatment: a Randomized Controlled Trial. Chest. 2018;154(6):1379–84.
Bellam BL, Dhibar DP, Suri V, Sharma N, Varma SC, Malhotra S, et al. Efficacy of tranexamic acid in haemoptysis: A randomized, controlled pilot study. Pulm Pharmacol Ther. 2016;40:80–3.
Kinoshita T, Ohbe H, Matsui H, Fushimi K, Ogura H, Yasunaga H. Effect of tranexamic acid on mortality in patients with haemoptysis: a nationwide study. Crit Care. 2019;23(1):347.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine. 2009;6(7):e1000097.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Wells G, Shea B, O'Connell D, Peterson j, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. á࿽࿽. 2000;á࿽࿽.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629.
Ruiz W. Acido tranexamico vs placebo en hemoptisis por TBC pulmonar: estudio pilato double ciego: PhD thesis; 1994.
Tscheikuna J, Chvaychoo B, Naruman C, Maranetra N. Tranexamic acid in patients with hemoptysis. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2002;85(4):399–404.
Alberto-Pasco C, Soto A. [Association of tranexamic acid to mortality and blood transfusion among patients with hemoptysis at Hipólito Unanue Hospital of Lima, Peru]. Revista peruana de medicina experimental y salud publica. 2013;30(2):357–8.
Fartoukh M, Khoshnood B, Parrot A, Khalil A, Carette MF, Stoclin A, et al. Early prediction of in-hospital mortality of patients with hemoptysis: an approach to defining severe hemoptysis. Respir Int Rev Thorac Dis. 2012;83(2):106–14.
Ong TH, Eng P. Massive hemoptysis requiring intensive care. Intensive care medicine. 2003;29(2):317–20.
Razazi K, Parrot A, Khalil A, Djibre M, Gounant V, Assouad J, et al. Severe haemoptysis in patients with nonsmall cell lung carcinoma. Eur Respir J. 2015;45(3):756–64.
Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis? Interactive cardiovascular and thoracic surgery. 2013;17(6):991–4.
Gadre A, Stoller J. Tranexamic Acid for Hemoptysis: A Review. Clinical Pulmonary Medicine. 2017;24:69–74.
Adams TR, Reeder JA, Alqassab F, Gilbert BW. Inhaled TXA for cases of massive hemoptysis. Am J Emerg Med. 2020;38(1):156–7.
Corey R, Hla KM. Major and Massive Hemoptysis: Reassessment of Conservative Management. Am J Med Sci. 1987;294(5):301–9.
Davidson K, Shojaee S. Managing Massive Hemoptysis Chest. 2020;157(1):77–88.
Patwa A, Shah A. Anatomy and physiology of respiratory system relevant to anaesthesia. Indian journal of anaesthesia. 2015;59(9):533–41.
Advanced trauma life. support (ATLS®): the ninth edition. The journal of trauma acute care surgery. 2013;74(5):1363–6.
Gnanadev R, Dong F, Ali A, Makkar G, Esiobu P, Vara R, et al. RS12. Comparing Mortality and Hospital Length of Stay in the Setting of Truncal and Peripheral Vascular Trauma in Patients Treated With Tranexamic Acid on Initial Presentation. J Vasc Surg. 2019;69:e188-e9.
Roberts I, Shakur-Still H, Afolabi A, Akere A, Arribas M, Brenner A, et al. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. The Lancet. 2020;395(10241):1927–36.
Myers SP, Kutcher ME, Rosengart MR, Sperry JL, Peitzman AB, Brown JB, et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. The journal of trauma acute care surgery. 2019;86(1):20–7.
Berman M, Cardone D, Sharples L, Vuylsteke A, Klein A, Gerrard C, et al. Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. Ann Thorac Surg. 2010;90(5):1432–6.
Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesenack C, et al. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg. 2011;39(5):e114-e21.
Krivokuca I, Lammers JW. Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. Clinical applied thrombosis/hemostasis: official journal of the International Academy of Clinical Applied Thrombosis/Hemostasis. 2011;17(1):106–7.
Seki N, Go S, Mayuko O, Shuji O, Reishi S, Seto T, et al. Risk Factors for a Second Episode of Hemoptysis. Clinical Medicine: Circulatory, Respiratory and Pulmonary Medicine. 2009;2009.
Lee MK, Kim SH, Yong SJ, Shin KC, Kim HS, Yu TS, et al. Moderate hemoptysis: recurrent hemoptysis and mortality according to bronchial artery embolization. Clin Respir J. 2015;9(1):53–64.
Choi J, Baik JH, Kim CH, Song SH, Kim SK, Kim M, et al. Long-term outcomes and prognostic factors in patients with mild hemoptysis. Am J Emerg Med. 2018;36(7):1160–5.

Additionalfile3.pdf
Additional file 3.pdf: Confounding factors that may affect the outcome of hemoptysis patients
Additionalfile4.pdf
Additional file 4.pdf: Meta-analysis evaluating minor adverse effect
Additionalfile2.pdf
Additional file 2.pdf: Risk of bias assessment for included studies
Additionalfile1.pdf
Additional file 1.pdf: Search strategy of this systemic review and meta-analysis

Download PDF

Version 1

posted

You are reading this latest preprint version

Effects of Tranexamic Acid on Hemoptysis: A Systematic Review and Meta-analysis

Status:

Version 1

Abstract

Figures

Background

Methods

Search strategy

Inclusion and exclusion criteria

Data extraction and management

Assessment of risk of bias

Statistical analysis

Result

Study characteristics

Risk of bias assessment

Primary outcome: overall mortality

Secondary outcome

Discussion

Conclusion

Abbreviations

Declarations

References

Supplementary Files

Status:

Version 1